Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands,and CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will present a company overview at the 2020 Wedbush PacGrow Healthcare Conference on Wednesday, August 12, 2020 at 10:20 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.

You May Also Be Interested In

• HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)
• ComEd Restores Power to 99% of Customers Impacted by Aug. 11-12 Storms
• The King Center and Divine Nine Launch Historic Fundraising Campaign to Preserve Critical History and Amplify Nonviolence365® Ahead of King100